What pharmacologic options are appropriate for treating insomnia in a patient who is not taking lithium?

Pharmacologic Treatment of Insomnia (Not on Lithium)

For patients not taking lithium who require pharmacologic treatment of insomnia, first-line options include low-dose doxepin (3-6 mg), nonbenzodiazepine BZRAs (zolpidem, eszopiclone, zaleplon), or orexin receptor antagonists (suvorexant, daridorexant), with cognitive behavioral therapy for insomnia (CBT-I) remaining superior to all pharmacologic options for long-term outcomes.

Treatment Algorithm

Step 1: Attempt CBT-I First

CBT-I demonstrates superior long-term efficacy compared to all pharmacologic interventions, with fewer adverse effects and sustained benefits beyond treatment cessation 1. While you're asking about pharmacologic options, understand that medications show equivalent short-term results (2-4 weeks) but inferior long-term outcomes compared to CBT-I 1.

Step 2: When Pharmacotherapy is Necessary

If the patient is unable or unwilling to receive CBT-I, proceed with medication selection based on the following:

Primary Options (Evidence-Based):

Low-dose doxepin (3-6 mg):

• Improves sleep latency, total sleep time, and sleep quality in both younger and older adults
• No statistically significant difference in adverse events versus placebo in trials
• No black box warning for suicide risk (though risk cannot be excluded)
• Effective for sleep maintenance
• Preferred in older adults 1

Nonbenzodiazepine BZRAs (zolpidem, eszopiclone, zaleplon):

• Improve sleep efficiency, sleep onset latency, sleep quality, total sleep time, and wake after sleep onset
• Benefits outweigh harms in short-term use
• Critical caveat: FDA safety warning for serious injuries from sleep behaviors (sleepwalking, sleep driving) while not fully awake 1
• Eszopiclone and zolpidem specifically have demonstrated efficacy for short-term global and sleep outcomes 2
• Should be avoided in older adults or those with respiratory/cognitive impairment 3

Orexin receptor antagonists (suvorexant, daridorexant):

• Can be used for periods up to 3 months or longer 4
• Daridorexant has Grade A recommendation for treatment 4
• Effective for both sleep initiation and maintenance 3
• Safer profile in older adults and those with mild cognitive impairment 3

Secondary Options:

Melatonin receptor agonists (ramelteon):

• Appropriate for older adults 5
• Prolonged-release melatonin can be used up to 3 months in patients ≥55 years 4

Trazodone:

• Most prescribed off-label treatment
• Efficacious for sleep initiation and maintenance
• Lacks abuse potential 3
• Useful in patients with comorbid depression 6

Step 3: Duration and Monitoring

Short-term use (≤4 weeks):

• Benzodiazepines, BZRAs, and low-dose sedating antidepressants are appropriate 4
• Use lowest effective dose for shortest duration 3

Longer-term considerations:

• Orexin receptor antagonists: up to 3 months or longer 4
• Other agents: longer-term use may be initiated in select cases, weighing advantages versus disadvantages 4
• Critical concern: Lack of clear harms data for pharmacologic treatments beyond brief periods raises concerns about increased risks with longer courses 1

Context-Specific Recommendations

For secondary insomnia with psychiatric comorbidities:

• Major depressive disorder: eszopiclone or trazodone 6
• Generalized anxiety disorder: eszopiclone or zolpidem 6
• PTSD: consider prazosin 6
• Bipolar manic episode: second-generation antipsychotic 6

For older adults (≥65 years):

• Prioritize low-dose doxepin, melatonin, ramelteon, or dual orexin receptor antagonists 5
• Avoid Z-hypnotics due to increased risks 3

Critical Pitfalls to Avoid

• Do not use antihistaminergic drugs, antipsychotics, fast-release melatonin, or phytotherapeutics—these are not recommended 4
• Do not use benzodiazepines long-term; observational studies suggest increased risk for dementia, fractures, and major injury 2
• Avoid BZRAs in patients with respiratory impairment, cognitive impairment, or advanced age 3
• FDA requires dose reduction in women and older adults for most hypnotics due to cognitive and behavioral changes, including driving impairment 2
• Always combine pharmacotherapy with sleep hygiene and behavioral approaches to optimize outcomes 7